Communiqués Bolt Biotherapeutics, Inc.

Actions

BOLT

US0977022039

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:30:00 28/08/2026			Varia. 5j.	Varia. 1 janv.
3,815 ^USD	-4,62 %		+4,09 %	-30,23 %

11/08	Bolt Biotherapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
12/05	Bolt Biotherapeutics publie ses résultats financiers du premier trimestre 2026	RE

Communiqués

11/08	Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot	AQ
11/08	Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
12/05	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot	AQ
12/05	Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
17/04	Bolt Biotherapeutics : BDC-4182 AACR Poster (BBI-4182-101 TiP AACR 2026 Final)	PU
12/03	Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot	AQ
12/03	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update	AQ
24/02	Bolt Biotherapeutics to Participate in Upcoming March Conferences	AQ
12/11	Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot	AQ
12/11	Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
01/10/25	Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027	AQ
14/08/25	Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot	AQ
14/08/25	Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update	AQ
12/05/25	Bolt Biotherapeutics : Presentation (2025-05-12-BOLT BDC-3042 Event)	PU
12/05/25	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot	AQ
12/05/25	Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update	GL
08/05/25	Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates	GL
08/05/25	Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates	AQ
30/04/25	Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025	GL
25/04/25	Bolt Biotherapeutics : PD-L1 AACR Poster (PDL1 AACR 2025 final print)	PU
25/04/25	Bolt Biotherapeutics : BDC 3042 AACR Poster (BDC 3042 AACR 2025 Poster v23Apr2025 Print)	PU
25/04/25	Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025	GL
21/04/25	Bolt Biotherapeutics : CEACAM5 AACR Poster (CEACAM5 2025 AACR poster FINAL)	PU
25/03/25	Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025	GL
24/03/25	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update	GL